리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2025년 08월
페이지 정보:영문 362 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 설포닐요소 시장은 2030년까지 108억 달러에 이를 전망
2024년에 97억 달러로 추정되는 설포닐요소 세계 시장은 2024-2030년의 분석 기간에 CAGR 1.8%로 성장하여 2030년에는 108억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 당뇨병 적응증은 CAGR 1.2%를 나타내고, 분석 기간 종료시에는 64억 달러에 이를 것으로 예측됩니다. 기타 적응증 부문의 성장률은 분석 기간중 CAGR 2.6%로 추정됩니다.
미국 시장은 26억 달러로 추정, 중국은 CAGR 3.5%로 성장 예측
미국의 설포닐요소 시장은 2024년에 26억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 분석 기간인 2024-2030년간 CAGR 3.5%로 2030년까지 20억 달러 규모에 이를 것으로 예측됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 0.6%와 1.3%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 약 0.9%를 보일 전망입니다.
세계의 설포닐요소 시장 - 주요 동향과 촉진요인 정리
설포닐요소는 곡물, 벼, 채소, 잔디밭의 광엽잡초와 벼과 식물의 방제에 널리 사용되는 제초제의 일종입니다. 이 화합물은 ALS(아세토락트산 합성효소)를 억제하고, 잡초의 생합성을 억제합니다. 최근 시장 동향은 다중 내성을 가진 잡초 집단으로의 전환을 반영하여 선택성, 토양 잔류성, 안전성 프로파일을 조정한 차세대 설포닐요소의 개발을 촉진하고 있습니다. 마이크로 캡슐화 및 나노 캐리어 전달과 같은 제형 개선은 토양 타겟팅을 강화하는 동시에 타겟 외 이동을 감소시킵니다.
농약 잔류에 대한 규제 모니터링은 독성이 낮고 분해 경로가 빠른 설포닐요소의 채택을 촉진하고 있습니다. 현재 많은 농약 제조업체들이 설포닐요소를 방출 제어형 제초제와 결합한 통합 패키지를 제공합니다. 디지털 살포 플랫폼과 가변 속도 어플리케이터는 정확도를 더욱 향상시키고, 효과를 높이면서 환경 부하를 줄입니다.
생화학 및 내성 문제는 어떻게 해결하고 있는가?
여러 ALS 억제제를 견딜 수 있도록 진화한 다제내성 잡초는 합성 옥신과 같은 독특한 활성 성분과 설포닐요소를 결합한 듀얼 모드 제초제에 대한 투자를 유도했습니다. 분자 설계에는 잡초의 대사를 억제하고 치료 기간을 연장하는 기능성 그룹이 포함되었습니다. 또한, 대사 프로파일링과 유전자 발현 분석은 표적 화합물의 최적화를 유도합니다. 토양 미생물에 대한 연구를 통해 과학자들은 화합물의 수명과 영향을 예측할 수 있게 되었으며, 영향을 받기 쉬운 지역에서도 안전하게 사용할 수 있게 되었습니다.
안정화 에멀젼과 생분해성 계면활성제를 특징으로 하는 새로운 제형은 뿌리 영역으로의 전달을 강화합니다. 이러한 시스템은 효과적인 방제를 위해 지속성이 충분하고 빠르게 분해되기 때문에 지하수 침투를 최소화하여 환경 기준을 충족할 수 있습니다.
누가, 어디서, 누가 이러한 솔루션을 채택하고 있는가?
아시아태평양의 고부가가치 작물 생산자, 특히 인도, 중국, 동남아시아의 쌀 재배 농가는 효율성과 낮은 면적당 비용으로 인해 선택적 설포닐요소에 크게 의존하고 있습니다. 유럽에서는 계절별 제초제 사용량을 줄이는 것을 목표로 하는 순환 재배 계획에서 저용량, 표적화된 제초제 사용을 선호하는 종합적인 잡초 관리 프로그램을 시행하고 있습니다. 북미의 보존형 농업 시스템에서는 무경운 시스템을 유지하면서 끈질긴 벼과 잡초를 처리하기 위해 조경작 사전 EM을 사용하고 있습니다.
라틴아메리카나 동아프리카의 신흥국에서는 마이크로 펠릿화된 설포닐요소를 드론 분무기로 살포하는 방식을 채택하여 균일한 살포범위를 확보하고 중복을 최소화하고 있습니다. 농업 서비스 플랫폼은 현재 제초제 서비스 모델을 제공하고 있으며, 농부들은 드론이나 트랙터로 계절에 따라 최적의 혼합제를 살포하기 위해 가입하고 있습니다.
설포닐요소 시장의 성장은 몇 가지 요인에 의해 주도되고 있습니다.
시장 확대는 제초제 내성 잡초 개체군 방제의 필요성에서 비롯되었으며, 듀얼 모드 활성제 및 용량 효율이 높은 블렌드의 기술 혁신을 촉진하고 있습니다. 정밀농업 기술(드론과 GPS를 이용한 마이크로 펠릿 살포)로 살포 범위가 확대되고 낭비를 최소화할 수 있습니다. 잔류물이 적고 분해 속도가 빠른 농약에 대한 규제 인센티브가 제품 재제조를 촉진합니다. 아시아 지역의 작물 집약화 및 이모작 관행은 살포 빈도를 증가시킵니다. 마지막으로, 서비스 기반 전달 모델은 개발도상국의 영세 농가의 도입 장벽을 낮춥니다.
부문
적응증(당뇨병, 기타 적응증), 제형(정제, 캡슐, 기타 제형), 최종 용도(병원, 전문 클리닉, 기타 최종 용도)
조사 대상 기업 예
Abbott Laboratories
Amgen Inc.
AstraZeneca plc
Bayer AG
Biocon Ltd.
Boehringer Ingelheim
Bristol-Myers Squibb
Eli Lilly and Company
GSK(GlaxoSmithKline)
Lupin Pharmaceuticals
Merck & Co., Inc.
Mylan(now part of Viatris)
Novartis International AG
Pfizer Inc.
Roche(Genentech subsidiary)
Sanofi S.A.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Torrent Pharmaceuticals Ltd.
Zydus Cadila(Cadila Healthcare)
AI 통합
당사는 유효한 전문가 컨텐츠와 AI툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.
Global Industry Analysts는 일반적인 LLM나 업계별 SLM 쿼리에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 대량 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.
관세 영향 계수
Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.
목차
제1장 조사 방법
제2장 주요 요약
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
스페인
러시아
기타 유럽
아시아태평양
호주
인도
한국
기타 아시아태평양
라틴아메리카
아르헨티나
브라질
멕시코
기타 라틴아메리카
중동
이란
이스라엘
사우디아라비아
아랍에미리트
기타 중동
아프리카
제4장 경쟁
LSH
영문 목차
영문목차
Global Sulfonylureas Market to Reach US$10.8 Billion by 2030
The global market for Sulfonylureas estimated at US$9.7 Billion in the year 2024, is expected to reach US$10.8 Billion by 2030, growing at a CAGR of 1.8% over the analysis period 2024-2030. Diabetes Indication, one of the segments analyzed in the report, is expected to record a 1.2% CAGR and reach US$6.4 Billion by the end of the analysis period. Growth in the Other Indications segment is estimated at 2.6% CAGR over the analysis period.
The U.S. Market is Estimated at US$2.6 Billion While China is Forecast to Grow at 3.5% CAGR
The Sulfonylureas market in the U.S. is estimated at US$2.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.0 Billion by the year 2030 trailing a CAGR of 3.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.6% and 1.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 0.9% CAGR.
Global Sulfonylureas Market - Key Trends & Drivers Summarized
Sulfonylureas constitute a class of herbicides widely used to control broadleaf weeds and grasses in cereal crops, rice, vegetables, and turf. Noted for their ultra-low dosage rates-often just grams per hectare-these compounds inhibit ALS (acetolactate synthase), disrupting weed biosynthesis. Recent market evolution reflects a shift towards multiple-resistance weed populations, prompting the development of next-gen sulfonylureas with tailored selectivity, soil persistence, and safety profiles. Formulation improvements, such as micro-encapsulation and nanocarrier delivery, enhance soil targeting while reducing off-target movement.
Regulatory scrutiny over agrochemical residues has driven adoption of sulfonylureas with low-toxicity and rapid degradation pathways. Many agrochemical leaders now offer integrated packaging-combining sulfonylureas with pre-emergent herbicides in controlled-release blends. Digital spraying platforms and variable-rate applicators further improve precision, reducing environmental load while increasing efficacy.
How Are Biochemical and Resistance Challenges Being Tackled?
ultiple-resistance weeds-evolved to withstand several ALS inhibitors-have triggered investment in dual-mode herbicides combining sulfonylureas with unique active ingredients like synthetic auxins. Molecular design now includes functional groups that reduce weed metabolism and elongate treatment windows. Additionally, metabolic profiling and gene-expression analytics guide targeted compound optimization. Soil microbiome studies are enabling scientists to predict compound longevity and impact, ensuring safe use in sensitive regions.
Novel formulations featuring stabilized emulsions and biodegradable surfactants enhance root-zone delivery. These systems persist just enough to provide effective control, then break down swiftly, minimizing groundwater infiltration and meeting environmental standards.
Who Is Adopting These Solutions and Where?
igh-value crop growers in Asia-Pacific-particularly rice farmers in India, China, and Southeast Asia-depend heavily on selective sulfonylureas due to their efficiency and low cost per area. In Europe, integrated weed management programs favor low-dose, targeted use within crop rotation plans aiming to reduce seasonal herbicide volume. North American conservation agriculture systems use strip-tilled pre-emergent blends to maintain no-till systems while tackling persistent grassy weeds.
Emerging economies in Latin America and East Africa are adopting micro-pelletized sulfonylureas distributed via drone sprayers, ensuring uniform coverage and minimizing overlap. Agricultural service platforms now offer herbicide-as-a-service models, where farmers subscribe to scheduled drone or tractor rigs delivering optimized mixes seasonally.
The Growth in the Sulfonylureas Market Is Driven by Several Factors…
he market’s expansion stems from the need to control herbicide-resistant weed populations, driving innovation in dual-mode actives and dosage-efficient blends. Precision ag technologies-drone and GPS-sprayed micro-pellets-expand reach and minimize waste. Regulatory incentives for low-residue, fast-degrading agrochemicals encourage product reformulation. Crop intensification and double cropping practices in Asia increase application frequency. Finally, service-based delivery models reduce barriers to adoption among smallholder farmers in developing regions.
SCOPE OF STUDY:
The report analyzes the Sulfonylureas market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Indication (Diabetes Indication, Other Indications); Form (Tablet Form, Capsules Form, Other Forms); End-Use (Hospitals End-Use, Specialty Clinics End-Use, Other End-Uses)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 32 Featured) -
Abbott Laboratories
Amgen Inc.
AstraZeneca plc
Bayer AG
Biocon Ltd.
Boehringer Ingelheim
Bristol-Myers Squibb
Eli Lilly and Company
GSK (GlaxoSmithKline)
Lupin Pharmaceuticals
Merck & Co., Inc.
Mylan (now part of Viatris)
Novartis International AG
Pfizer Inc.
Roche (Genentech subsidiary)
Sanofi S.A.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Torrent Pharmaceuticals Ltd.
Zydus Cadila (Cadila Healthcare)
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Tariff Impact on Global Supply Chain Patterns
Sulfonylureas - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Global Diabetes Prevalence Throws the Spotlight Back on Affordable Oral Hypoglycemic Agents
Favorable Pricing and Established Safety Profiles Sustain Use of Sulfonylureas in Cost-Constrained Healthcare Systems
Generic Competition and Expiry of Patents Expand Access and Volume Sales in Emerging Economies
Integration into Combination Therapies Enhances Therapeutic Versatility in Type 2 Diabetes Treatment
Clinical Preference for Sulfonylureas in Initiation Therapy Maintains Relevance in Low-Resource Settings
Increased Demand for Step-Wise Treatment Protocols Drives Continued Role of Sulfonylureas in Sequential Therapy
Global Public Health Programs and WHO Essential Drug Listings Promote Adoption in National Formularies
Adoption of Value-Based Care Models Strengthens Business Case for Economical Diabetes Management Solutions
Comparative Cost Advantage Over New-Age Antidiabetics Preserves Market Share in Public Sector Institutions
Growing Investment in Patient Education and Adherence Support Reaffirms Sulfonylurea Prescriptions
Development of Modified-Release Formulations Improves Tolerability and Reduces Hypoglycemia Risk
Rising Use of e-Prescriptions and Clinical Decision Tools Supports Rational Sulfonylurea Utilization
Ongoing Pharmacovigilance and Real-World Evidence Studies Sustain Clinical Confidence in Legacy Drug Class
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Sulfonylureas Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Sulfonylureas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Sulfonylureas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 4: World 16-Year Perspective for Sulfonylureas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Diabetes Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Diabetes Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 7: World 16-Year Perspective for Diabetes Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 10: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Tablet Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Tablet Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 13: World 16-Year Perspective for Tablet Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Capsules Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Capsules Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 16: World 16-Year Perspective for Capsules Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Other Forms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Other Forms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 19: World 16-Year Perspective for Other Forms by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 22: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 24: World Historic Review for Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 25: World 16-Year Perspective for Specialty Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 27: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 28: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Sulfonylureas Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 29: USA Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 30: USA Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 31: USA 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 32: USA Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 33: USA Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 34: USA 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
TABLE 35: USA Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 36: USA Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 37: USA 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
CANADA
TABLE 38: Canada Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 39: Canada Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 40: Canada 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 41: Canada Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 42: Canada Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 43: Canada 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
TABLE 44: Canada Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 45: Canada Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 46: Canada 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
JAPAN
Sulfonylureas Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 47: Japan Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 48: Japan Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 49: Japan 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 50: Japan Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 51: Japan Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 52: Japan 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
TABLE 53: Japan Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 54: Japan Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 55: Japan 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
CHINA
Sulfonylureas Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 56: China Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 57: China Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 58: China 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 59: China Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 60: China Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 61: China 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
TABLE 62: China Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 63: China Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 64: China 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
EUROPE
Sulfonylureas Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 65: Europe Recent Past, Current & Future Analysis for Sulfonylureas by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 66: Europe Historic Review for Sulfonylureas by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 67: Europe 16-Year Perspective for Sulfonylureas by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
TABLE 68: Europe Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 69: Europe Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 70: Europe 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 71: Europe Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 72: Europe Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 73: Europe 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
TABLE 74: Europe Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 75: Europe Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 76: Europe 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
FRANCE
Sulfonylureas Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 77: France Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 78: France Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 79: France 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 80: France Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 81: France Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 82: France 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
TABLE 83: France Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 84: France Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 85: France 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
GERMANY
Sulfonylureas Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 86: Germany Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 87: Germany Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 88: Germany 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 89: Germany Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 90: Germany Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 91: Germany 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
TABLE 92: Germany Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 93: Germany Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 94: Germany 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
ITALY
TABLE 95: Italy Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 96: Italy Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 97: Italy 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 98: Italy Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 99: Italy Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 100: Italy 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
TABLE 101: Italy Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 102: Italy Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 103: Italy 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
UNITED KINGDOM
Sulfonylureas Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 104: UK Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 105: UK Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 106: UK 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 107: UK Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 108: UK Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 109: UK 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
TABLE 110: UK Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 111: UK Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 112: UK 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
SPAIN
TABLE 113: Spain Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 114: Spain Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 115: Spain 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 116: Spain Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 117: Spain Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 118: Spain 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
TABLE 119: Spain Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 120: Spain Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 121: Spain 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
RUSSIA
TABLE 122: Russia Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 123: Russia Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 124: Russia 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 125: Russia Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 126: Russia Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 127: Russia 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
TABLE 128: Russia Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 129: Russia Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 130: Russia 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
REST OF EUROPE
TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 132: Rest of Europe Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 133: Rest of Europe 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 135: Rest of Europe Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 136: Rest of Europe 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 138: Rest of Europe Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 139: Rest of Europe 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
ASIA-PACIFIC
Sulfonylureas Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Sulfonylureas by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 141: Asia-Pacific Historic Review for Sulfonylureas by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 142: Asia-Pacific 16-Year Perspective for Sulfonylureas by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 144: Asia-Pacific Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 145: Asia-Pacific 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 147: Asia-Pacific Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 148: Asia-Pacific 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 150: Asia-Pacific Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 151: Asia-Pacific 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
AUSTRALIA
Sulfonylureas Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 152: Australia Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 153: Australia Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 154: Australia 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 155: Australia Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 156: Australia Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 157: Australia 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
TABLE 158: Australia Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 159: Australia Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 160: Australia 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
INDIA
Sulfonylureas Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 161: India Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 162: India Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 163: India 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 164: India Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 165: India Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 166: India 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
TABLE 167: India Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 168: India Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 169: India 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
SOUTH KOREA
TABLE 170: South Korea Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 171: South Korea Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 172: South Korea 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 173: South Korea Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 174: South Korea Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 175: South Korea 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
TABLE 176: South Korea Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 177: South Korea Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 178: South Korea 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 180: Rest of Asia-Pacific Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 181: Rest of Asia-Pacific 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 183: Rest of Asia-Pacific Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 184: Rest of Asia-Pacific 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 186: Rest of Asia-Pacific Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
LATIN AMERICA
Sulfonylureas Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 188: Latin America Recent Past, Current & Future Analysis for Sulfonylureas by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 189: Latin America Historic Review for Sulfonylureas by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 190: Latin America 16-Year Perspective for Sulfonylureas by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
TABLE 191: Latin America Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 192: Latin America Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 193: Latin America 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 194: Latin America Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 195: Latin America Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 196: Latin America 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
TABLE 197: Latin America Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 198: Latin America Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 199: Latin America 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
ARGENTINA
TABLE 200: Argentina Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 201: Argentina Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 202: Argentina 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 203: Argentina Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 204: Argentina Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 205: Argentina 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
TABLE 206: Argentina Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 207: Argentina Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 208: Argentina 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
BRAZIL
TABLE 209: Brazil Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 210: Brazil Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 211: Brazil 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 212: Brazil Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 213: Brazil Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 214: Brazil 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
TABLE 215: Brazil Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 216: Brazil Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 217: Brazil 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
MEXICO
TABLE 218: Mexico Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 219: Mexico Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 220: Mexico 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 221: Mexico Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 222: Mexico Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 223: Mexico 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
TABLE 224: Mexico Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 225: Mexico Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 226: Mexico 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
REST OF LATIN AMERICA
TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 228: Rest of Latin America Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 229: Rest of Latin America 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 231: Rest of Latin America Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 232: Rest of Latin America 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 234: Rest of Latin America Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 235: Rest of Latin America 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
MIDDLE EAST
Sulfonylureas Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 236: Middle East Recent Past, Current & Future Analysis for Sulfonylureas by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 237: Middle East Historic Review for Sulfonylureas by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 238: Middle East 16-Year Perspective for Sulfonylureas by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
TABLE 239: Middle East Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 240: Middle East Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 241: Middle East 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 242: Middle East Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 243: Middle East Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 244: Middle East 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
TABLE 245: Middle East Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 246: Middle East Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 247: Middle East 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
IRAN
TABLE 248: Iran Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 249: Iran Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 250: Iran 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 251: Iran Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 252: Iran Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 253: Iran 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
TABLE 254: Iran Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 255: Iran Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 256: Iran 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
ISRAEL
TABLE 257: Israel Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 258: Israel Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 259: Israel 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 260: Israel Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 261: Israel Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 262: Israel 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
TABLE 263: Israel Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 264: Israel Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 265: Israel 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
SAUDI ARABIA
TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 267: Saudi Arabia Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 268: Saudi Arabia 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 270: Saudi Arabia Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 271: Saudi Arabia 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 273: Saudi Arabia Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 274: Saudi Arabia 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 275: UAE Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 276: UAE Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 277: UAE 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 278: UAE Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 279: UAE Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 280: UAE 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
TABLE 281: UAE Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 282: UAE Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 283: UAE 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
REST OF MIDDLE EAST
TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 285: Rest of Middle East Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 286: Rest of Middle East 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 288: Rest of Middle East Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 289: Rest of Middle East 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 291: Rest of Middle East Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 292: Rest of Middle East 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
AFRICA
Sulfonylureas Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 293: Africa Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 294: Africa Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 295: Africa 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 296: Africa Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 297: Africa Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 298: Africa 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
TABLE 299: Africa Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 300: Africa Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 301: Africa 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030